Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mereo Biopharma Group Plc ( (MREO) ).
On January 12, 2026, Mereo BioPharma provided a corporate update detailing the status of its rare disease pipeline and financial position. Following Phase 3 Orbit and Cosmic trials in osteogenesis imperfecta that failed to meet primary fracture-reduction endpoints but showed strong gains in bone mineral density and a consistent safety profile, the company has reduced and delayed pre-commercial and manufacturing activities for setrusumab while conducting further data analyses and considering regulatory interactions with partner Ultragenyx. In parallel, Mereo is pushing ahead with partnering talks and key preparations for a single global Phase 3 trial of alvelestat in alpha-1 antitrypsin deficiency-associated lung disease, and highlighted progress on vantictumab, which has been out-licensed to āshibio for autosomal dominant osteopetrosis type 2 with a Phase 2 study planned for the second half of 2026. The company reported approximately $41 million in cash and cash equivalents as of December 31, 2025, and updated its guidance to indicate this balance is expected to fund operations through mid-2027, underscoring tighter cost controls and providing greater visibility for investors as Mereo navigates mixed clinical outcomes and seeks partners to share late-stage development and commercialization risk.
The most recent analyst rating on (MREO) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
The score is driven primarily by weak financial performance (large losses and cash burn with minimal revenue) and very bearish technical signals (well below major moving averages with negative MACD). A negative Phase 3 trial update further pressures the outlook, while the low leverage balance sheet provides some offsetting support.
To see Spark’s full report on MREO stock, click here.
More about Mereo Biopharma Group Plc
Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases. Its pipeline includes setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2, alongside additional partnered programs in reproductive medicine and oncology, with various orphan, fast track and breakthrough designations supporting its niche rare-disease market positioning.
Average Trading Volume: 10,609,720
Technical Sentiment Signal: Sell
Current Market Cap: $61.16M
For detailed information about MREO stock, go to TipRanks’ Stock Analysis page.